Showing 1 - 5 results of 5 for search 'Luzelena Caro', query time: 0.03s Refine Results
  1. 1
    Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection

    Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection by Nancy Reau, Michael N. Robertson, Hwa‐Ping Feng, Luzelena Caro, Wendy W. Yeh, Bach‐Yen T. Nguyen, Janice Wahl, Eliav Barr, Peggy Hwang, Stephanie O. Klopfer

    Published 2017-10-01
    Get full text
    Article
  2. 2
    A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults

    A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults by Yuji Orito, Naoyuki Otani, Yuki Matsumoto, Katsukuni Fujimoto, Nobuyuki Oshima, Brian M. Maas, Luzelena Caro, Antonios O. Aliprantis, Kara S. Cox, Osamu Tokumaru, Masaaki Kodama, Hideo Kudo, Hiromitsu Imai, Naoto Uemura

    Published 2022-07-01
    Get full text
    Article
  3. 3
    Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults

    Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of... by Jia Yao Phuah, Brian M. Maas, Aimin Tang, Ying Zhang, Luzelena Caro, Radha A. Railkar, Michael D. Swanson, Yu Cao, Hankun Li, Brad Roadcap, Andrew P. Catchpole, Antonios O. Aliprantis, Kalpit A. Vora

    Published 2023-12-01
    Get full text
    Article
  4. 4
    Elbasvir/grazoprevir in children aged 3–18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study

    Elbasvir/grazoprevir in children aged 3–18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study by Regino P. Gonzalez-Peralta, Stefan Wirth, Robert H. Squires, Frauke Mutschler, Thomas Lang, Malgorzata Pawlowska, Wojciech Sluzewski, Ewa Majda-Stanislawska, Bjorn Fischler, William F. Balistreri, Maureen M. Jonas, Niviann Blondet, Philip Rosenthal, Naim Alkhouri, Rene Romero, Anjana Grandhi, Patricia Castronuovo, Luzelena Caro, Lihong Du, Daniel I.S. Rosenbloom, Barbara A. Haber

    Published 2023-03-01
    Get full text
    Article
  5. 5
    Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis

    Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis by Brian M. Maas, Jos Lommerse, Nele Plock, Radha A. Railkar, S.Y. Amy Cheung, Luzelena Caro, Jingxian Chen, Wen Liu, Ying Zhang, Qinlei Huang, Wei Gao, Li Qin, Jie Meng, Han Witjes, Emilie Schindler, Benjamin Guiastrennec, Francesco Bellanti, Daniel S. Spellman, Brad Roadcap, Mariya Kalinova, Juin Fok-Seang, Andrew P. Catchpole, Amy S. Espeseth, S. Aubrey Stoch, Eseng Lai, Kalpit A. Vora, Antonios O. Aliprantis, Jeffrey R. Sachs

    Published 2021-11-01
    Get full text
    Article

Search Tools: